Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
54.23M | 57.56M | 50.58M | 47.68M | 50.83M | 45.85M | Gross Profit |
37.09M | 39.69M | 29.75M | 28.29M | 35.84M | 32.88M | EBIT |
-41.18M | -30.77M | -15.10M | -42.07M | -34.68M | -42.89M | EBITDA |
-35.35M | -26.62M | 1.18M | -39.58M | -45.11M | -39.15M | Net Income Common Stockholders |
-54.24M | -44.14M | -7.87M | -60.20M | -90.04M | -65.36M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
68.66M | 71.55M | 23.87M | 27.27M | 28.02M | 31.81M | Total Assets |
102.23M | 101.42M | 57.42M | 55.67M | 61.99M | 62.88M | Total Debt |
39.13M | 38.00M | 33.32M | 56.09M | 56.42M | 40.48M | Net Debt |
-29.52M | -33.54M | 9.45M | 28.82M | 28.40M | 8.67M | Total Liabilities |
163.16M | 161.58M | 163.91M | 174.23M | 144.13M | 111.38M | Stockholders Equity |
-60.93M | -60.16M | -106.49M | -118.55M | -82.13M | -48.50M |
Cash Flow | Free Cash Flow | ||||
-49.04M | -35.92M | -7.38M | -12.31M | -33.89M | -45.98M | Operating Cash Flow |
-48.77M | -35.76M | -6.38M | -9.79M | -32.98M | -45.46M | Investing Cash Flow |
-265.00K | -159.00K | -995.00K | -2.52M | -913.00K | -517.00K | Financing Cash Flow |
22.50M | 83.59M | 3.97M | 11.56M | 30.11M | 28.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $157.95M | ― | -48.14% | ― | -29.69% | -105.88% | |
55 Neutral | $32.12M | ― | -2.12% | ― | 12.82% | 96.46% | |
54 Neutral | $5.34B | 3.27 | -45.10% | 3.30% | 16.80% | 0.02% | |
53 Neutral | $339.70M | ― | 77.48% | ― | 5.29% | -37.31% | |
52 Neutral | $231.89M | ― | 23.44% | ― | 12.99% | 17.78% | |
52 Neutral | $339.24M | ― | -21.63% | ― | -18.56% | 76.88% | |
46 Neutral | $246.96M | ― | -83.58% | ― | 6.88% | -17.54% |
On June 16, 2025, Aquestive Therapeutics announced that the FDA accepted its New Drug Application for Anaphylm™, an orally delivered epinephrine for treating severe allergic reactions, with a PDUFA target action date set for January 31, 2026. If approved, Anaphylm would be the first oral epinephrine option in the U.S., potentially transforming anaphylaxis care by addressing barriers such as fear of administration and the inconvenience of carrying bulky devices.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
On June 11, 2025, Aquestive Therapeutics, Inc. held its Annual Meeting of Stockholders, where key decisions were made. Daniel Barber and Timothy E. Morris were elected as Class I members of the Board of Directors for a three-year term. Additionally, the stockholders approved executive compensation on a non-binding advisory basis and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Aquestive Therapeutics has announced plans regarding the advancement of its product candidates, including Anaphylm, a sublingual film for epinephrine, and AQST-108, a topical gel for alopecia areata. The company is preparing for potential FDA approvals and market launches, which could significantly impact its market positioning and offer new alternatives in the treatment of these conditions.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Aquestive Therapeutics reported its first quarter 2025 financial results and provided a business update, highlighting the submission of a New Drug Application (NDA) for Anaphylm, an oral sublingual film for severe allergic reactions. The company plans a potential U.S. launch in early 2026, subject to FDA approval, and is focusing resources on this launch, pausing other projects. Financially, the company saw a 28% decrease in total revenues compared to the first quarter of 2024, primarily due to a decline in manufacture and supply revenue. The net loss increased to $22.9 million, driven by higher selling, general, and administrative expenses.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
On April 1, 2025, Aquestive Therapeutics announced positive results from its pediatric study for Anaphylm™ (epinephrine) Sublingual Film, marking the completion of its clinical program. The company has submitted a New Drug Application (NDA) to the FDA, expecting potential acceptance in the second quarter of 2025. The study involved patients aged seven to seventeen, showing consistent pharmacokinetic results with previous adult studies, and no serious adverse events were reported. Aquestive plans to launch Anaphylm in the first quarter of 2026, pending FDA approval.